MOLINA HEALTHCARE, INC. (MOH): debt financing — Molina Healthcare adds $500M delayed draw term loan facility via credit agreement amendment

MOLINA HEALTHCARE, INC.

Delayed Draw Term Loan facility of $500M established under amended credit agreement dated Feb 19, 2025.
Available until June 19, 2025; matures Feb 19, 2027; draws for general corporate purposes.
Applicable margin: 0.125% (base) / 1.125% (SOFR); ticking fee of 0.25% p.a. on unused portion.
Other terms substantially similar to prior credit agreement; no change to existing revolving facility.
Lenders include Truist Bank, Barclays, Deutsche Bank, MUFG, JPMorgan, Goldman Sachs, Citizens, Huntington, U.S. Bank.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

MOLINA HEALTHCARE, INC. incurred credit facility of $500,000,000 with Truist Bank, as Administrative Agent, Issuing Bank and Swingline Lender at 0.125% for base rate loans and 1.125% for SOFR based loans maturing February 19, 2027.

Instrument: credit facility
Principal: $500,000,000
Counterparty: Truist Bank, as Administrative Agent, Issuing Bank and Swingline Lender
Rate: 0.125% for base rate loans and 1.125% for SOFR based loans
Maturity: February 19, 2027
Event: incurrence

Exact text from the filing

Commitment” and a new Section 2.5 were added to reflect the establishment of a Delayed Draw Commitment under the Amended Credit Agreement in an aggregate principal amount of $500,000,000 and Sections 3.2 and 5.9 were revised to reflect that Delayed Draw Term Loans (as defined in the Amended Credit Agreement) may be drawn for general corporate purposes of the

View on SEC.gov

41 debt financings filed in the last 30 days. Browse all debt financings →

MOLINA HEALTHCARE, INC. filing history →

Source: SEC EDGAR

accession 0001437749-25-004747

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.